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Abstract 
Objective: type III Hyperlipoproteinemia is a rare lipid
disorder with a frequency of 1-5 in 5000. It is charac-
terized  by  the  accumulation  of  triglyceride  rich
lipoproteins and patients are at increased risk of de-
velopping atherosclerosis. type III HlP is strongly as-
sociated with the homozygous presence of the ʵ2 al-
lele of the APOE gene.
However only about 10%of subjectswith aPoE2/2
genotype develop hyperlipidemia and it is therefore as-
sumed that further genetic and environmental factors
are necessary for the expression of disease. It has re-
cently been shown that variation in the APOA5 gene
is one of these co-factors. the aim of this study is to
investigate the development of cerebrovascular athero  -
sclerosis  in  patients  with  type  III  hyperlipopro  -
teinemia (type III HlP) and the role of variation in
the aPoa5 gene as a risk factor.
Methods: 60 patients with type III hyperlipidemia and
apoE2/2 genotype were included in the study after
informed  consent.  the  presence  of  cerebrovascular
atherosclerosis  was  investigated  using  b-mode  ultra-
sonography of the carotid artery. serum lipid levels
were  measured  by  standard  procedures.the  aPoE
genotype and the 1131t>C and s19W snPs in the
aPoa5 gene and the aPoC3 sstI snP were deter-
mined by restriction isotyping. allele frequencies were
determined  by  gene  counting  and  compared  using
Fisher’s  exact  test.  Continuous  variables  were  com-
pared using the Mann Whitney test. a p value of 0.05
or below was considered statistically significant. analy-
sis was performed using statistica 7 software.
Results: the  incidence  of  the  aPoa5  snPs,  -
1131t>C and s19W and the aPoC3 sstI snP were
determined as a potential risk modifier. after correc-
tion for conventional risk factors, the C allele of the -
1131t>C  snP  in  the  aPoa5  gene  was  associated
with an increased risk for the development of carotid
plaque in patients with type III HlP with an odds ra-
tio of 3.69. Evaluation of the genotype distribution
was  compatible  with  an  independent  effect  of
aPoa5.
Conclusions:  the  development  of  atherosclerosis  in
patients with type III HlP is modulated by variation
in the APOA5 gene. 
Key  words: type III Hyperlipoproteinemia, apolipo  -
protein a5,  apolipoprotein C3, atherosclerosis, gene
variation
IntRoduCtIon
type III HlP is a rare disorder of lipid metabolism
with a frequency of approximately 1-5 in 5000 and is
characterized by the accumulation of triglyceride rich
lipoprotein remnant particles in the form of b-vldl
and homozygosity for the ʵ2 allele of the aPoE gene
[reviewed in 1]. Patients present with elevated and ap-
proximately  equal  levels  of  plasma  cholesterol  and
triglycerides  and  are  at  increased  risk  of  developing
atherosclerosis. almost all patients with type III HlP
are homozygous for the ʵ2 allele of the aPoE gene
although only about 10% of subjects with aPoE2/2
genotype develop the condition [1] and it is assumed
that further genetic and/or environmental factors are
necessary for the expression of disease. It has been
shown  that  variation  in  the  aPoa5  gene  is  one  of
these  co-factors  [2,  3].  apolipoprotein  a5  (apoa5)
contributes to triglyceride metabolism in both humans
and animal models. In humans, apoa5 mutations show
an association with elevated plasma triglyceride levels
in most studies confirming the role of apoa5 in lipid
metabolism. Family studies of apoa5 variants indicat-
ed  a  variable  mode  of  inheritance  and  a  low  pene-
trance of hyperlipidemia. thus co-existence of other
hyperlipidemic factors such as diabetes mellitus, envi-
ronmental factors or additional disturbances in lipid
metabolism are required for expression of hyperlipi-
demia.the recessive mode of inheritance and the low
penetrance may explain why the results from human
studies are not as clear as predicted from animal stud-
ies [4]. this is especially true for clinical consequences
of  hyperlipidemia:  whereas  some  studies  showed  an
association of apoa5 with atherosclerosis, others did
not [5-11]. one explanation of the variable findings is
the  complex  association  of    aPoa5  variants  with 
other apolipoprotein genes: the apoa5 gene is part of
the aPoa/aPoC3/aPoa4/aPoa5 gene cluster on
chromosome 11q23. a number of studies, reviewed
by lai et al [12], have investigated the haplotype struc-
ture of this region. Whereas the aPoa5*3 haplotype,
defined  by  the  s19W  snP,  is  independent  of  the
aPoC3  snPs,  the  aPoa5*2  haplotype  defined  by
the  -1131t>C  snP  is  strongly  associated  with  the
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somes with aPoa5*2 containing the minor allele of
sstI. It is therefore of interest to determine the fre-
quency of the aPoC3 sstI snPs in order to evaluate
the effect of variation in the aPoa5 gene. Further in-
sight  into  the  role  of  apo  a5  can  be  obtained  by
analysing well defined patient entities in order to re-
strict other variables. as it is unclear if the overrepre-
sentation of apoa5 variants in patients with type III
HlP is associated with  increased atherosclerosis, we
investigated this question in a patient collective with
type III HlP.
the aims of our study were therefore firstly to de-
termine  the  incidence  of  atherosclerosis  as  deter-
mined  by  b-mode  ultrasonography  of  the  carotid
artery  and secondly to investigate the factors which
lead to the development of carotid plaque in this high
risk population with a special focus on APOA5 vari-
ants. 
MEtHods
PaRtICIPants
Patients  with  mixed  hyperlipidemia  and  APOE 2/2
genotype who have attended the lipid clinic, univer-
sit￤tsklinikum Hamburg-Eppendorf, since 1997 were
eligible  for  the  study.  details  of  this  patient  group
have  been  described  previously  [2,  13].  60  patients
with type III HlP were included into the study. all
Probands gave informed consent and the study was
approved by the Ethik-Kommission of the ￄrztekam-
mer Hamburg.
CaRotId atHERosClERosIs
to eliminate inter-operator variability, carotid b-mode
ultrasonography  was  performed  by  a  single  trained
sonographer  unaware  of  the  study  design  using  a
vivid III expert from GE, using a 7,5 MHz transduc-
er. Patients were measured bilatererally at three levels,
following the protocol used in the Framingham study
[14]. Intima-media thickness (IMt) is presented as the
mean in mm of the measurements obtained for the
common carotid artery (CCa) and the internal carotid
artery (ICa). the common carotid arteries, both bifur-
cations and the internal carotid arteries were evaluated
for the presence of plaque at the time of the ultra-
sound measurement. 
bIoCHEMICal MEasuREMEnts
Plasma cholesterol (tC) and triglycerides (tG) were
determined using the GPo-PaP and CHod-PaP kits
respectively  from  boehringer  Mannheim.  Hdl  was
determined following precipitation of apo b contain-
ing  lipoproteins  with  phosphotungstate  (boehringer
Mannheim). lp(a) was determined using the beckman
array 360 (beckman Instruments). 
GEnotyPInG
the APOE genotype, the 1131t>C and s19W snPs
in the APOA5 gene, and the sstI snP in the APOC3
gene were determined as described [2, 15,16].
statIstICal MEtHods
allele frequencies were determined by gene counting
and  compared  using  Fisher’s  exact  test.  Continuous
variables were compared using the Mann Whitney test.
a p value of 0.05 or below was considered statistically
significant. analysis was performed using statistica 7
software.
REsults
the clinical characteristics of the individual patients
are presented in table 1. Plaque was detected in the
carotid bulb in 25 (42%) of patients. the mean IMt
of patients with plaque was greater (aCC 0.88 mm,
bulb  1.40  mm)  than  those  without  (aCC  0.75  mm
bulb 0.99 mm), p = 0.0001 for the difference in aCC
and 0.00002 for the difference in the carotid bulb. 
Comparing the incidence of the traditional risk fac-
tors for the development of atherosclerosis in type
III HlP patients with and without plaque there was
no significant difference in the proportion of smok-
ers/ex-smokers to never smokers, (15/25 and 24/35
respectively) or women (8/25 and 10/35). there were
no significant differences in the levels of lp(a) or in
the occurrence of type 2 diabetes, (2/25 and 6/35),
and  hypertension,  (8/25  and  7/35).  although,  as  is
usual with type III HlP, mean bMI was high there
was  no  significant  difference  between  patients  with
plaque  (27.9ﾱ3.5)  and  those  without  (28.0ﾱ4.3).  by
definition all patients had elevated plasma levels of to-
tal cholesterol and triglycerides. there were no signifi-
cant differences in total cholesterol, triglycerides and
Hdl  cholesterol  between  patient  groups.  However,
comparison is difficult since for clinical reasons lipid
lowering therapy could not be discontinued for a pro-
portion of the patients. However for 16 patients with
and 24 without plaque lipid values were obtained in
the  absence  of  lipid  lowering  therapy.  Patients  with
plaque  had  higher  total  cholesterol,  400ﾱ174mg/dl
compared to patients without, 291ﾱ124, p = 0.047 .
there was no significant difference in triglyceride lev-
els. no further subgroup analysis of lipid levels was
performed  due  to  small  patient  group  size.  Patients
with plaque were significantly older, mean age 54 years
compared to 46 years for those without, p = 0.002. 
the frequency of the -1131t>C snP in APOA5
was compared in patients with plaque to that in those
without (table 2 a,b). the C allele was significantly
more frequent in patients with plaque, 0.24 (12/25),
than  in  those  without,  0.10  (7/35),  p  =  0.035.  the
odds  ratio  for  carriers  of  the  C  allele  to  develop
plaque was 3.69. In multiple regression analysis with
presence or absence of plaque as dependent variable
and  age,  bMI,  smoking,  hypertension,  dM2,  sex,
lp(a) and APOA5-1131t>C genotype as independent
variables only age (p = 0.002) and APOA5-1131t>C
genotype (p = 0.041) were significant factors. Inclu-
sion of total cholesterol and triglycerides in the analy-
sis but exclusion of patients from whom we had no
lipid values in the absence of lipid lowering therapy (n
= 40) reduced the significance of age, p = 0.032 and
increased the significance of aPoa5 genotype, p =
0.023.  no  other  factors  were  statistically  significant.
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Table 1. Clinical characteristics of patients with bulbar plaque present or absent.
A) Plaque present
Pat aGE sEX IMt IMt lp(a) smoker d Ht KHK avK CvI Chol trig Hdl
num aCC -bulb M
years M/F mm mm mg/dl s/ex/n 2
101 37 M 0.75 0.90 105 n- - - - - 481 588 69
76 41 M 0.93 1.83 6y -+-+-265 674 54
90 44 M 0.75 0.88 54 y- - + - - 426 418 41
36 44 M 0.67 1.45 2y -----418 983 53
35 45 M 0.70 1.50 <2 EX -+ + + -268 558 46
44 45 M 0.83 1.48 3y -----439 476 36
28 47 M 0.85 15 y- - - - - 316 634 53
86 50 F 0.80 0.95 2y -----484 636 71
63 50 M 0.78 1.10 <2 n- - - - - 240 364 37
4 52 F 0.95 1.75 11 n- + - - - 651 433 44
87 52 M 0.83 1.03 <2 n- + - - - 182 418 41
20 53 F 1.08 1.90 4y -----503 360 47
45 53 M 0.95 1.00 8y ---+-273 315 37
71 55 M 1.10 1.60 3 EX -+ --+ 441 716 68
27 55 M 0.95 1.45 <2 n+ + + - - 317 560 40
48 55 F 1.25 1.83 <2 n- - - - - 428 460 42
37 57 F 0.90 1.43 11 y- - - - - 435 388 46
52 59 M 1.08 1.63 <2 y- - - - + 137 69 57
38 48 M 0.83 1.23 15 y- - - - - 292 428 39
93 61 F 32 y- + - - - 341 777 33
6 62 F 0.70 1.05 22 n- - - - - 336 411 50
16 62 M 0.80 1.13 <2 n- - - - - 416 405 49
89 65 M 0.83 1.28 9- - + - - 393 555 44
3 69 M 0.92 2.15 10 EX -+ --331 548 41
91 76 F 0.90 1.55 7n +
Mean 53.5 0.88 1.40 13 367 507 47
n 25 17/8 12/3/9 28432
B) Plaque absent
Pat aGE sEX IMt IMt- lp(a) smoker dM2 Ht KHK avK CvI Chol trig Hdl
num aCC bulbus
years m/f mm mm s/ex/n
46 28 M 0.80 1.58 10 y- - - - - 246 143 41
100 30 M 0.73 1.05 19 y- - - - - 694 1118 44
40 31 M 0.77 0.80 4y -----201 261 29
72 32 M 0.67 0.85 3- - - - - 446 729 51
33 34 M 0.70 0.88 7y -----
62 36 M 0.60 0.67 10 n- - - - - 202 177 65
60 37 M 0.67 1.05 3y -----225 293 37
65 38 F 0.72 0.93 <2 EX -+ ---377 949 40
97 38 M 0.60 0.83 2 EX -----408 402 69
21 39 M 0.70 0.98 3y -----143 266 32
73 39 F 0.75 0.88 10 EX -----579 519 55
102 40 M 0.78 0.93 19 n- - - - - 196 165 52
5 41 F 0.65 0.65 27 n+ - - - - 598 939 57
14 41 F 0.73 0.98 9 EX -----255 120 63
50 42 M 0.68 1.05 15 EX -+ + --251 407 29
8 42 M 0.65 0.65 <2 y- - - - - 154 258 41
95 42 F 0.90 1.55 11 EX -+ + --286 473 35
61 43 M 0.63 0.92 4 EX -----360 678 57
12 43 M 0.80 0.98 7y -----149 92 56
64 44 M 0.80 0.73 17 y+ + - - - 444 932 49
47 47 M 0.78 0.95 4n -----483 641 35
85 47 M 0.73 0.78 <2 EX -----380 727 50
94 48 M 1.05 1.03 <2 n- + - - - 285 313 54
11 50 M 0.77 0.93 14 y- - - - - 343 513 40
1 50 F 0.60 0.85 8y -----532 311 57
53 51 M 0.92 1.00 49 EX --+ --252 198 41
25 51 M 0.70 0.98 <2 -+ ---414 682 38
98 56 M 0.70 <2 y+ - - - - 399 762 48
34 56 F 0.77 1.40 8 EX +- +- - 665 1640 78
59 58 M 0.85 1.30 <2 n- - - - - 204 282 62
31 60 F 0.80 1.05 52 n- - - - - 397 283 70
23 61 M 0.73 1.03 56 EX ++- - - 442 709 50
74 63 F 0.80 1.23 15 EX -----211 323 42
70 70 F 0.83 1.43 13 n- - - - - 473 609 65
66 74 M 0.85 1.08 5n +-+-+276 752 56
Mean 46 0.75 0.99 12 354 558 50
n 35 25/10 12/12/10 67501
Patients are listed in order of increasing age. + = presence of dM2 or hypertension ( Ht ); IMt in mm; lp(a) in mg/dl
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of the W allele of the s19W snP between patients
with plaque 0.10 and those without 0.14. the frequen-
cy of the minor allele of the aPoC3 sstI snP was
significantly  higher  in  type  III  HlP  patients  with
plaque,  0.2,  compared  to  those  without,  0.07  (p  =
0.03, Fisher’s exact, two-tailed, table 2c). Comparing
the  dis  tribution  of  the  genotypes  aPoC3GG/
aPoa5tt/aPoa5ss  and  aPoC3GC/aPoa5tC/
aPoa5ss amongst patients with or without plaque,
we found an equal distribution in patients with plaque,
9  with  each  genotype  whereas  in  patients  without
plaque there was only one double heterozygote com-
pared to 18 with the common haplotype (p = 0.003,
Fisher’s exact, two-tailed). all four patients with geno-
type aPoC3GC/aPoa5tt/aPoa5ss did not have
plaque.
dIsCussIon
the principal finding of this investigation is that the -
1131t>C snP in the aPoa5 gene is a risk factor for
the  development  of  carotid  plaque  in  patients  with
type III HlP. although this snP has been consistent-
ly  associated  with  elevated  triglycerides  and  lower
Hdl in a number of studies [13, 17-20], its associa-
tion with the development of atherosclerosis has been
inconsistent with positive associations being reported
in some, but not all studies [5-12]. the inconsistent re-
sults reported may be explained  by a relatively modest
functional influence of such a common genetic variant
and by the recessive mode of disease expression as
well as inheritance. these characteristics of apoa5 will
result in considerable genetic and phenotypic variabili-
ty in the population under study. With this background
a major advantage of our study is that type III HlP
patients represent a well-defined, homogeneous group.
this patient collective has a number of conventional
risk  factors  in  common  providing  a  uniform  back-
ground in which to investigate the role of variants in
candidate  genes.  by  investigating  patients  with  the
same APOE genotype one source of genetic variabili-
ty is eliminated.  this applies not only to the reduction
of variability for dyslipidemia but also for the clinical
consequence of atherosclerosis since the APOE geno-
type has been associated in a number of studies with
carotid phenotype [reviewed in 21]. 
although APOE 2/2 genotype is required for the
development  of  type  III  HlP  only  approximately
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A) Plaque present
Pat aPoC3 aPoa5 aPoa5
num sstI 1131t>C s19W
rs5128 rs662799 rs3135506
101
76
90 GC tC
36 tC
35
44 GC tC
28
86 sW
63 GC tC
4 GC tC
87 GC tC
20 GC tC
45 GC tC
71 tC
27
48 sW
37 GC tC
52
38 sW
93 GC tC
6
16
89
3 sW
91 GC tC sW
n 10 12 5
B) Plaque absent
Pat aPoC3 aPoa5 aPoa5
num sstI 1131t>C s19W
rs5128 rs662799 rs3135506
46
100
40
72 WW
33 tC
62 GC
60
65
97 GC
21 GC tC
73
102
5 sW
14 tC
50 sW
8 tC
95
61 tC
12
64
47 GC
85 tC sW
94
11
1
53
25
98
34 GC
59
31
23 sW
74 tC sW
70 sW
66 sW
n577/1
C:  Summary  of  APOA5  and  APOC3  polymorphism  fre-
quencies
APOC3 APOA5 APOA5 Plaque Plaque
sstI -1131T>C S19W Present Absent
GG tt ss 9 18
GG tC ss 24
GG tt sW 45
GG tC sW 02
GG tt WW 01
GC tt ss 04
GC tC ss 91
GC tC sW 10
Table 2. aPoa5 and aPoC3 polymorphism frequencies in patients with bulbar plaque present or absent.
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implying that additional genetic and/or environmental
factors are necessary for its expression [1]. We suggest
that variation of apoa5 may be one of these factors
not only for expression of hyperlipidemia [2] but also
for the clinical endpoint of atherosclerosis. How could
apoa5 modulate disease expression in type III HlP ?
It has been shown that apoa5 upregulates lipolysis by
binding  to  heparin  sulphate  proteoglycans  (HsPG,
[22]). the interaction of apoE with HsPG plays an im-
portant role for the expression of type III HlP in ad-
dition to its reduced binding to lipoprotein receptors
[23]. We postulate that intact apoa5 may be able to at
least in part compensate the reduced HsPG interaction
of apoE2, whereas apoa5 variants with either reduced
synthesis or structural defects may not, thus resulting
in the necessary second defect for expression of type
III HlP. Proof of this principle has been shown for
lipoprotein lipase (lPl) variants, where defects in lPl
were detected in patients with type III HlP as second
dyslipidemic  factor  in  addition  to  the  presence  of
apoE  2  [24].    Recent  in  vitro  structure  –  function
analysis of apoa5 variants is compatible with the pos-
tulated  coordinated  interaction  of  apoE,  lPl  and
apoa5 [25]. these variants, which do not induce hy-
perlipidema in isolated form or may not be identifiable
as risk factor in a unselected population, may be un-
masked  in  combination  with  variants  in  other  target
genes  as  in  the  presented  study.  In  case  of  the  -
1131t/C exchange, which is located in the promotor
region of apoa5 reduced synthesis of apoa5 may re-
sult in decreased protein levels and thus reduced coor-
dinated protein-protein or protein-HsPG interactions.
alternatively synthesis rates may be influenced by the
a>G exchange at position – 3, which is linked to the -
1131t/C exchange as part of the aPoa5*2 haplotype.
Results from in vitro expression studies do not show a
functional effect of the single variant, however a coop-
erative  effect  of  these  variants  on  protein  synthesis
cannot  be  ruled  out  [26].  In  addition  the  aPoa5*2
haplotype is in significant linkage disequilibrium with
the sstI polymorphism and two promotor variants in
the aPoC3 gene, the 482 t and the -455 C allele [27].
these variants are located in the insulin responsive ele-
ment of the promotor region of the aPoC3 gene and
are associated with plasma tri  glyceride levels [28]. to
evaluate  the  separate  effects  of  variation  in  the
APOA5 and APOC3 gene it is therefore important to
determine the frequency of the aPoC3 sstI snP in
our type III HlP patients in addition to the analysis of
the 1131t/C exchange. the frequency of the minor al-
lele of the aPoC3 sstI snP was significantly higher in
type III HlP patients with plaque, 0.2, compared to
those  without,  0.07  (p  =  0.03,  Fisher’s  exact,  two-
tailed), which is not unexpected and reflects the linkage
of the alleles as part of the aPoa5*2 haplotype. In
order to dissect the effects of the GC allele in aPoC3
and the tC allele in aPoa5 the distribution of the
genotypes  aPoC3GG/aPoa5tt/aPoa5ss  and
aPoC3GC/aPoa5tC/aPoa5ss  amongst  patients
with or without plaque was analysed. both variant alle-
les  were  significantly  more  frequent  in  patients  with
plaque as compared to patients without plaque. How-
ever the presence the GC allele was not associated with
plaque, when combined with a tt allele, whereas a sig-
nificant association of the GC allele with plaque was
obeserved in the presence of a tC allelle. these data
imply that it is the 1131t/C exchange in the APOA5
gene which is associated with plaque in patients with
type III HlP. 
the major weakness of our study is the small num-
ber of patients available for analysis. this is due to the
rarity of type III HlP, (in our clinic 72/2545 patients
attending over a ten year period), with a frequency of
type III HlP of 1-5 in 5000. the 60 patients included
in this study therefore represent an estimated popula-
tion of 60,000-300,000. Confirmation of our findings
in other populations is necessary. the analysis of the
frequency of candidate snPs for atherosclerosis in a
small but homogeneous patient group adds important
information  to  studies  in  large  more  heterogeneous
groups when investigating the effect of common poly-
morphisms on complex traits such as atherosclerosis.
ConClusIon
In  conclusion  we  present  evidence  that  -1131t>C
snP in the APOA5 gene influences the development
of coronary plaque in a group of patients at high risk,
namely those with type III HlP indicating a role of
apoa5 not only in dyslipidemia but also in the patho-
physiology of atherosclerosis.
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